Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
ADMA rides on margin gains, supply deals, and IVIG shift into 2026, but valuation and recent stock decline add complexity for investors.
Adma Biologics (ADMA) Laps the Stock Market: Here's Why
Adma Biologics (ADMA) concluded the recent trading session at $9.95, signifying a +1.22% move from its prior day's close.
ADMA Biologics: The Short Report Is The Noise, Not The Signal
ADMA Biologics (ADMA) remains a Buy after a 40% stock decline, with Asceniv's niche demand and premium pricing intact. Concerns about rising DSO are mitigated by falling distributor inventory and strong 51% YoY revenue growth. Management expects DSO improvement in 2026, supported by a diversified distribution network and a focus on working capital.
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
ADMA rides on surging Asceniv demand, expanding payer coverage, and stronger plasma supply deals to drive rapid revenue growth through 2027.
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Adma Biologics (ADMA) settling at $9.01, representing a -1.53% change from its previous close.
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Adma Biologics (ADMA) closed the most recent trading day at $9.63, moving 15% from the previous trading session.
Down 27% in 4 Weeks, Here's Why Adma Biologics (ADMA) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Adma Biologics (ADMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
New Strong Buy Stocks for March 25th
EQT, BCBP, FIX, PAAS and ADMA have been added to the Zacks Rank #1 (Strong Buy) List on March 25, 2026.
New Strong Buy Stocks for March 23rd
LCUT, EFXT, MGA, ADMA and JLL have been added to the Zacks Rank #1 (Strong Buy) List on March 23, 2026.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $15.02, denoting a +1.01% move from the preceding trading day.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
